SCHEMBL1031097

SCHEMBL1031097

CC1CCC(Nc2ncc(-c3cccc(OC(F)F)c3)cn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 2/20 0.42
GALR1 P47211 2/20 0.42
EGFR P00533 6/20 0.41
BTK Q06187 6/20 0.41
DRD1 P21728 1/20 0.40
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
PDE1A P54750 1/20 0.39
PDE1B Q01064 1/20 0.39
PDE1C Q14123 1/20 0.39
CCNT1 O60563 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1031098 1.00 GALR2 (0.42) GALR2GALR1EGFRBTKDRD1
SCHEMBL1332139 0.89 GABRA1 (0.43) USP2ALDH1A1LMNACYP1A2CYP3A4
SCHEMBL1332135 0.89 GABRA1 (0.43) USP2ALDH1A1LMNACYP1A2CYP3A4
SCHEMBL1334057 0.85 GALR2 (0.42) GALR2GALR1DRD1LMNAMAPK1
SCHEMBL1334058 0.85 GALR2 (0.42) GALR2GALR1DRD1LMNAMAPK1
SCHEMBL1332909 0.79 GRM5 (0.39) DRD1USP2ALDH1A1LMNACYP1A2
SCHEMBL1332911 0.79 GRM5 (0.39) DRD1USP2ALDH1A1LMNACYP1A2
SCHEMBL6885645 0.77 GRM5 (0.48) MAPK1CCNT1IRAK4MAPT
SCHEMBL1334209 0.74 GRM5 (0.41) ALDH1A1MAPK1IRAK4ABL1MAPT
SCHEMBL1334210 0.74 GRM5 (0.41) ALDH1A1MAPK1IRAK4ABL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS GALR2 4500/4885GALR1 4245/4885EGFR 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.